Home Contact Center Add this

Debiopharm International S.A.

developing & financing innovative drugs

Debiopharm International SA searches, evaluates and in-licenses promising drug candidates for development. Towards the end of the development process, the products are licensed out to pharmaceutical companies for world-wide marketing and sales.

 

 

Bertrand Ducrey

Bertrand Ducrey

Chief Executive Officer, Debiopharm International S.A.

Dr Ducrey received his Diploma of Pharmacy from the School of Pharmacy of Lausanne University, Switzerland in 1990 and then obtained his Ph.D. in Pharmaceutical Sciences in 1995. He joined Debiopharm Research & Manufacturing SA in 1995 as Pharmaceutical Project Manager. He then spent two years at Debiopharm International SA as Innovative Formulation Manager. In 2004, he returned to Debiopharm Research & Manufacturing to head the company as Chief Executive Officer until 2011. Since 2012, Dr Ducrey heads Debiopharm International SA as CEO.

Tom Gibbs

Tom Gibbs

Vice-President ad interim Business Development & Licensing, Debiopharm International S.A. 
& Director Debiopharm Diagnostics S.A.

Dr Gibbs received his BSc in Applied Biology from the University of Wales Institute of Science and Technology, and earned his Ph.D. in Microbial Genetics at the University of Warwick. He has spent more than two decades in the commercialization of life science technologies, split equally between the pharmaceutical industry and scientific tool developers. He has been responsible for a wide range of activities including quality assurance, operations, late-stage product development and marketing, and increasingly business development. Dr. Gibbs has broad experience in both start-ups (Cytion, Covalys, Med Discovery) and more established companies (Delta Biotechnology, Molecular Devices, Debiopharm) in Europe and the USA. He joined Debiopharm International SA in 2012.

Nigel McCracken

Nigel McCracken

Vice President, Translational Medicine & Vice President ad interim Clinical Research & Development, Debiopharm International S.A.

Dr McCracken obtained his BSc in Biochemistry/Pharmacology from Strathclyde University, UK in 1988 and a PhD in Biochemical Toxicology from Newcastle University, UK in 1991. Following a post-doctoral position in pharmacogenetics, Dr McCracken moved into pharma, where he worked for Charles River and Abbot Laboratories within the field of DMPK. In 2005, Dr McCracken moved to Altana Pharma/Nycomed (Konstanz, DE) as Senior Director of DMPK and then in 2008 became VP of Exploratory & Translational Development. In 2010 joined Shire (Eysins, VD) to Head up Translational Medicine, with a focus on implementing modern translational concepts of drug development with the ultimate goal to bring to the market and position medicines that matter. He joined Debiopharm International SA in 2014.

Christine Deuschel

Christine Deuschel

Senior Vice President, Portfolio & Project Management, Debiopharm International S.A.

Dr Deuschel has been trained as chemist and received her Ph.D. in Science from the faculty of Sciences of the University of Fribourg, Switzerland in 1987. She later completed an MBA from HEC and EPFL, Lausanne, Switzerland, in 2007. Previous job experiences include post-graduate research at the University of California at Berkeley, Faculty member of the University of Bern, Switzerland. Dr Deuschel has also been Chief Operating Officer, and then Chief Executive Officer at Athelas SA Geneva, Switzerland, a start up company active in the fields of antibacterial drug-discovery, and Chief Scientific Officer at Anteis SA Geneva, Switzerland. She joined Debiopharm International SA in 1995.

Houssam Ibrahim

Houssam Ibrahim

Vice President Pharmaceutical Development, Debiopharm International S.A.

Dr Ibrahim received his Diploma of Pharmacy from the Faculty of Sciences of the University of Geneva, Switzerland in 1983, and in 1989, obtained his Ph.D. in Sciences from the ‘Laboratoire de Pharmacie Galénique’, University of Geneva. Dr Ibrahim has acquired international experience in the pharmaceutical industry, including quality assurance, regulatory affairs, pharmaceutical sciences and GMP productions for clinical trial materials and commercial products. Previous job experiences include work in Quality Assurance and Regulatory Affairs at Serono. He joined Debiopharm International SA in 1992.

Peggy Lipp

Peggy Lipp

Director, Regulatory Affairs, Business Intelligence & Market Access, Debiopharm International S.A.

Mrs Lipp received her M.Sc. (Dipl. Ing.) degree in Biotechonology from Technical university of Graz in Austria and is experienced in leading the development of global regulatory strategies in a broad number of therapeutic areas for both early and late stage products. Before joining Debiopharm, Ms. Lipp was Director of Regulatory Affairs in Janssen, where she was directly responsible for successful key product approvals across multiple therapeutic areas. Prior to joining Janssen, she held multiple regulatory and research positions with increasing responsibilities in Biogen, Baxter, ApoPharma, and Mount Sinai School of Medicine. She joined Debiopharm in 2015 to lead Regulatory Affairs, Market Access and Business Intelligence teams.

Daniel Brandt

Daniel Brandt

Director, Quality Management & Documentation, Debiopharm International S.A.

Dr Brandt graduated from the Faculty of Sciences of the University of Geneva, Switzerland in 1975 and obtained a Ph.D. in Biology (Immunology) in 1980. Previous job experiences include Clinical Project Manager at Socar (Société pour la Recherche en Cardiologie) in Nyon then Clinical Research Associates Coordinator at Dupont Pharma in Geneva. He joined Debiopharm International SA in 1994 to establish Quality Assurance in clinical research.

Manuela Perraudin

Manuela Perraudin

Director, Human Resources, Debiopharm International S.A.

Mrs Perraudin obtained a Degree in International Relations from the Graduate Institute of International Studies in 1992 and a Master of Business Administration from the IMD, in 2002. With 21 years’ experience in Human Resources, she has held several senior management positions in the medical technology, hi-tech and engineering industries. She spent seven years at Medtronic Europe as Human Resources Director of the European Cardiovascular Division, subsequently held the position of Corporate Vice President Human Resources at Advanced Digital Broadcast and then became the Global Division Vice President Human Resources at IMI Hydronics, an organization including 6 manufacturing sites and 2000 employees in Europe, Asia and America. She joined Debiopharm International in 2014.

Alexandre Maret

Alexandre Maret

Director Finance and Administration - Debiopharm International S.A.

Mr Maret received his Enterprise Economist diploma from the University of Applied Sciences, Western Switzerland (HES SO)  in 1996. He has acquired an extensive experience in the accounting services of several companies (bank, international fiduciary, e-business). He joined Debiopharm International SA in 2005.

Vanessa Currat

Vanessa Currat

Director, Legal Affairs, Debiopharm International S.A.

Mrs. Currat graduated from the University of Paris V - René Descartes, where she obtained a Master of Business Law ("DESS") in 1994, followed by a Master of International Economical Law from Paris I – La Sorbonne ("DEA") the same year. She started with trainee positions in a law firm (Kimbrough & Associates) and in the industrial field (Alcatel-Lucent) in Paris. She then gained experience working in the industrial field (Vetrotech-Saint-Gobain) and in a medical device company in Switzerland. She joined Debiopharm International SA in 1996 where she developed solid expertise as both lawyer and IP Counsel, becoming IP Manager in 2000. Since implementing the merge of the IP and Legal Services in 2006, she has been the head of Legal Affairs of Debiopharm Group.

Debiopharm International S.A.

Forum "après-demain"
Chemin Messidor 5-7
Case postale 5911
1002 Lausanne
Switzerland

Tel. +41 (0)21 321 0111
Fax. +41 (0)21 321 0169